
|Articles|January 29, 2008
Clot-dissolving agent gains additional shelf life
ImaRx Therapeutics' urokinase gains an additional 20 months of expiration dating
Advertisement
ImaRx Therapeutics' urokinase has received an additional 20 months of expiration dating. This means the clot buster from the Tucson, Ariz., firm's most recent lot will have a prolonged shelf life. The thombolytic is indicated for the treatment of acute massive pulmonary embolism.
To see more Daily News articles,
To go to the Drug Topics homepage,
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Enflonsia for the Prevention of RSV Lower Respiratory Tract Disease in Infants
2
The Emergence of CGRP-Targeted Therapies is Transforming Migraine Care | NCPA 2025
3
Pharmacists Experience Challenges in Credentialing, Billing for Services | NCPA 2025
4
FDA Approves Tezepelumab for as Add-On Treatment for Chronic Rhinosinusitis With Nasal Polyps
5